Preferred Label : Rebastinib;
NCIt definition : An orally bioavailable small-molecule inhibitor of multiple tyrosine kinases with
potential antineoplastic activity. Upon oral administration, rebastinib binds to and
inhibits the Bcr-Abl fusion oncoprotein by changing the conformation of the folded
protein to disallow ligand-dependent and ligand-independent activation; in addition,
this agent binds to and inhibits Src family kinases LYN, HCK and FGR and the receptor
tyrosine kinases TIE-2 and VEGFR-2. Rebastinib may exhibit more potent activity against
T315I Bcr-Abl gatekeeper mutant kinases than other Bcr-Abl kinase inhibitors. The
TIE-2 and VEGFR-2 receptor tyrosine kinases regulate angiogenesis, respectively, while
the Src family kinases Abl, LYN, and HCK Src regulate a variety of cellular responses
including differentiation, division, adhesion, and the stress response.;
UNII : 75017Q6I97;
InChIKey : WVXNSAVVKYZVOE-UHFFFAOYSA-N;
CAS number : 1020172-07-9; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1020172-07-9
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : DCC-2036;
NCI Metathesaurus CUI : CL553494;
Origin ID : C152162;
UMLS CUI : C4519282;
Automatic exact mappings (from CISMeF team)
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
